Pancreatic ductal adenocarcinoma (PDAC), which constitutes 90% of pancreatic cancers, is
the fourth leading cause of cancer-related deaths in the world. Due to the broad …

Background FOLFIRINOX is a standard treatment for metastatic pancreatic cancer patients.
The effectiveness of neoadjuvant FOLFIRINOX in patients with borderline resectable …

Objective: For patients with locally advanced and unresectable pancreatic cancer (PDAC),
neodadjuvant treatment and consecutive surgical exploration have been studied during the …

Purpose: On the basis of the ACCORD trial, FOLFIRINOX is effective in metastatic pancreatic
adenocarcinoma (PDAC), making it a rational choice for locally advanced PDAC (LA). Aims …

Thanks to the development of modern chemotherapeutic regimens, survival after surgery for
pancreatic ductal adenocarcinoma (PDAC) has improved and pancreatologists worldwide …

Importance Although consensus statements support the preoperative treatment of borderline
resectable pancreatic cancer, no prospective, quality-controlled, multicenter studies of this …

The NCCN Guidelines for Pancreatic Adenocarcinoma discuss the diagnosis and
management of adenocarcinomas of the exocrine pancreas and are intended to assist with …

Background and Objectives Sarcopenia, which is subclinical loss of skeletal muscle mass, is
commonly observed in patients with malignancy. The objective of this study is to determine …

Background Recent years have seen standardization of the anatomic definitions of
pancreatic adenocarcinoma, and increasing utilization of neoadjuvant therapy (NAT). The …

Objective The use of neoadjuvant chemotherapy can enable surgical resection of borderline
resectable or unresectable pancreatic cancer (PC). The aim of this study was to evaluate the …